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Abstract
Background: Smoking cause airway and systemic inflammation and COPD patients present low grade inflammation 
in peripheral blood. However, data on the influence of smoking itself on systemic inflammation in COPD patients are 
scarce. This study investigated the association between inflammation, smoking status, and disease.
Methods: A cross-sectional analysis comparing 53 COPD ex-smokers, 24 COPD current smokers, 24 current smoker 
controls and 34 never-smoker controls was performed. Assessments included medical history, body composition, 
spirometry, and plasma concentration of tumor necrosis factor-alpha (TNF-α), interleukins (IL)-6, IL-8, and C-reactive 
protein (CRP).
Results: Our exploratory analysis showed that serum TNF-α was higher in COPD current smokers [4.8(4.2-5.8)pg/mL] 
and in current smoker controls [4.8 (4.2-6.1) pg/mL] when compared to COPD ex-smokers [4.3 (3.9-4.9)pg/mL; p = 0.02] 
and to never-smoker controls [3.7 (3.4-4.0)pg/mL; p < 0.001]. Multiple regression results with and without adjustment 
for covariates were consistent with the hypothesis that TNF-α levels were associated with smoking status in both 
models (p < 0.001 and p < 0.001). IL-6 and CRP were significantly higher in COPD patients when compared to smoker 
and never-smoker controls and the multiple regression analysis confirmed the association of these mediators with 
disease, but not with smoking status (p < 0.001 and p < 0.001). IL-8 had only a borderline association with disease in 
both models (p = 0.069 and p = 0.053). No influence of disease severity, inhaled corticosteroid, fat-free mass (FFM) 
depletion and long term oxygen therapy (LTOT) use on systemic inflammation was found.
Conclusion: Smoking may influence TNF-α mediated systemic inflammation, which, in turn, may account for some of 
the benefits observed in patients with COPD who stop smoking.
Background
Cigarette smoking is a major risk factor for chronic
obstructive pulmonary disease (COPD). Long-term
smoking causes airway inflammation characterized by
neutrophil, macrophage, and activated T lymphocyte
infiltration and by increased cytokine concentrations
such as tumor necrosis factor-alpha (TNF-α), interleu-
kins (IL)-6 and IL-8 [1-4]. Although nearly all smokers
show some evidence of lung and systemic cellular and/or
humoral inflammation, only a few will suffer an amplified
response and develop COPD [5,6].
Several studies have shown systemic inflammation in
COPD patients with increased neutrophil, macrophage,
and T-lymphocyte numbers and high concentrations of
inflammatory mediators in peripheral blood (C-reactive
protein (CRP), IL-6, IL-8 and TNF-α) [7-12]. TNF-α, a
powerful pro-inflammatory cytokine primarily produced
by activated macrophages, is thought to play a critical
role in the pathogenesis of COPD by promoting and
maintaining the expression and release of various proin-
flammatory mediators which lead to tissue damage and
remodeling [13,14].
Very little is known about the mechanism of increased
TNF-α concentration in the plasma of COPD patients
and its relationship with disease severity and active
smoking has not been established [9,15]. Evaluation of
soluble receptors, an indirect marker of proinflammatory
state related to systemic TNF-α, showed no influence of
smoking on systemic inflammation in small sample of
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COPD patients [16]. However, in a study with the aim to
examine levels of inflammatory markers in COPD and
asthma patients, the influence of smoking on TNF-α
serum concentration was identified only in the subgroup
of COPD patients [12]. We hypothesed that active smok-
ing may be associated with more severe systemic inflam-
mation in COPD patients. In order to test our hypothesis,
we analyzed concentrations of TNF-α, IL-6, IL-8 and
CRP in the peripheral blood of current smoker and ex-
smoker COPD patients, with a wide range of airway, cur-
rent smoker and never-smoker controls.
Methods
Subjects
Seventy seven clinically stable COPD (mild to very
severe) patients, 53 ex-smokers (for at least 1 year) and 24
current smokers, followed-up at the Outpatient Pul-
monology Unit of Botucatu Medical School - Brazil par-
ticipated in the study. COPD was diagnosed according to
the GOLD criteria: post-bronchodilator (400 mcg fenot-
erol) FEV1/FVC ratio < 70% without significant revers-
ibility (<11% predicted FEV1 or 200 ml) in the presence of
respiratory symptoms and a smoking history of at least 20
pack-years [17]. Exclusion criteria included oral steroid
use or exacerbations in the last three months before
enrollment in the study, diagnosis of other chronic dis-
eases (i.e. diabetes, renal failure and cancer) or other
respiratory disease (i.e. asthma, bronchiectasis, bronchi-
olitis or tuberculosis). Further 24 current smoker controls
(at least 10 pack-years) with no evidence of COPD, other
diseases or using regular medication and 34 never-
smoker controls were also recruited. Smokers and never-
smoker controls underwent routine clinical assessments
including spirometry and chest X-ray. Ethical approval
was obtained from Ethical Committee of Botucatu Medi-
cal School - Brazil and all subjects gave written informed
consent.
Pulmonary function test and peripheral oxygen saturation
Forced expiratory volume in the first second (FEV1) and
forced vital capacity (FVC) were obtained from the flow-
volume curve using a spirometer (Ferraris KOKO, Louis-
ville, CO, USA) before and 20 minutes after β-agonist
(fenoterol 400 mcg) inhalation. The highest value of at
least three measurements was selected and expressed as a
percentage of reference values [18]. Pulse oximetry
(SpO2%) was assessed by a portable oxymeter (Nonin
Medical, Plymouth, MN, USA).
Body composition
Height and weight were measured and body mass index
(BMI) calculated (kg/m2). Fat-free mass (FFM), in kg, was
estimated using bioelectrical impedance analysis (BIA
101, RJL systems, Detroit, MI, USA) according to Euro-
pean Society Parenteral Enteral Nutrition guidelines [19]
using specific equations for COPD patients and healthy
controls [20,21]. FFM index (FFMI) was calculated as
FFM/height2  (kg/m2). FFM depletion was diagnosed
when FFMI < 15 kg/m2 for females and <16 kg/m2 for
males was present [22].
Blood sampling and analysis
Fasting peripheral blood was collected early morning
(08.00-10.00 hours) and plasma stored at -80°C until anal-
ysis. TNF-α, IL-6, and IL-8 were assessed in duplicate by
high sensitivity commercial kits using enzyme linked
immunosorbent assay (ELISA) according to manufac-
turer's instructions (BioSource International Inc, Ca,
USA). Lower detection limit was 0.5 pg/mL for TNF-α,
0.16 pg/mL for IL-6, and 0.39 pg/mL for IL-8. C-reactive
protein (CRP) was assessed in duplicate by high sensitiv-
ity particle enhanced immunonephelometry (Cardio-
Phase, Dade Behring Marburg GmbH, Marburg, USA)
with a lower detection limit of 0.007 mg/L.
Statistical analysis
All variables were summarized using means and standard
deviations. To compare groups defined by smoking status
and presence of disease (COPD) on demographic and
general characteristics we used Chi-square tests for cate-
gorical variables and analysis of variance (ANOVA) for
continuous variables, using the Tukey test to account for
multiple comparisons. Kruskal-Wallis tests were used to
evaluate group differences for the inflammation measures
with Dunn's method used to adjust for multiple compari-
sons [23]. We analyzed the association of smoking status
(current smoking or no-smoking) and presence of disease
(COPD) with systemic inflammation (TNF-α, IL-6, IL-8
and CRP) using a multiple linear regression with robust
standard errors with and without adjustment for poten-
tial confounders (age, gender, SpO2 and FFM). Statistical
significance was considered when p < 0.05. (STATA soft-
ware 9.0 - STATA Corp, College Station, Texas, USA).
Results
Populations Characteristics
Demographics, baseline lung function, and body compo-
sition of never-smoker and current smoker controls,
COPD ex-smokers and COPD current smokers are pre-
sented in Table 1. COPD patients tended to be older than
current smoker controls and never-smoker controls;
smoking history (pack-years) was similar in COPD
patients and current smoker controls. As expected,
COPD patients had significant airflow limitation and
decreased SpO2 compared to never-smoker and current
smoker controls. Twelve COPD patients were at GOLD
stage I, 28 GOLD stage II, 14 GOLD stage III, and 23
GOLD stage IV. Sixty five patients were using long-termTanni et al. Journal of Inflammation 2010, 7:29
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broncodilators and seventeen (tree COPD current smok-
ers and 14 ex-smokers) patients were regularly using
inhaled corticosteroid (800 mcg of budesonide), 16 had
been on stable oxygen flow therapy for the last six
months. No patients were medicated with theophylline or
leukotriene modifiers.
FFM depletion was seen in COPD patients compared to
never-smoker controls (Table 1). Five (14.7%) never-
smokers, four (16.7%) current smoker controls and thirty
seven (48.1%) COPD patients showed FFM depletion;
however, the prevalence was not statistically different
between groups (p = 0.46).
Plasma levels of TNF-α, IL-6, IL-8, and CRP
Plasma TNF-α was higher in current smoker controls and
COPD current smokers when compared to never-smoker
controls, and COPD ex-smokers (Table 2). The regression
results, both, with and without adjustment for age, gen-
der, SpO2 and FFM also showed a positive association
between active smoking and TNF-α (Table 3). We did not
found difference in serum TNF-α between the groups
according the use of inhaled corticosteroid (p = 0.49).
Plasma CRP was higher in both groups of COPD
patients when compared to never-smoker and current
smoker controls. IL-6 also was higher in both groups of
COPD patients when compared to never-smoker controls
and also was higher in COPD ex-smokers when com-
pared to current smoker controls (Table 2). Unadjusted
regression results also showed an association between
CRP, IL-6 and the presence of the COPD; however, no
association with active smoking was detected. IL-8 had
only a borderline association with COPD in both models
(p = 0.069 and p = 0.053) (Table 3).
We compared systemic inflammation in COPD patients
according to GOLD stage, presence of nutritional deple-
tion (FFMI), and long term oxygen therapy (LTOT) and
no difference was found between groups (data not
shown).
Discussion
This study aimed to evaluate the relationship between
systemic inflammation and smoking status in COPD
patients. The main finding was that current smokers pre-
sented significantly higher plasma levels of TNF-α com-
pared to no-smokers. These results suggest that smoking
may be associated with higher TNF-α mediated systemic
inflammation in COPD patients who are current smok-
ers. We also reinforce previous findings that patients with
COPD, regardless of smoking status, present evidence of
systemic inflammation when compared to control sub-
jects.
Table 1: Demographics, lung function, and body composition of never-smoker controls and current smoker controls and 
COPD patients, according to smoking status
Never-smoker controls
N = 34
Current smokers
controls
N = 24
COPD
ex-smokers
N = 53
COPD
Current smokers
N = 24
p value
Age (years) 49.1 ± 8.3 48.6 ± 6.6 66.5 ± 7.7* 57.5 ± 9.3†† <0.001
Gender (M/F%) 50/50 58/42 75/25§ 46/54§ 0.03
FEV1 (L) 3.3 ± 0.7 2.9 ± 0.8 1.3 ± 0.7* 1.5 ± 0.9* <0.05
FEV1 (%) 111.2 ± 15.2 105.4 ± 16.2 56.3 ± 25.5* 59.4 ± 22.1* <0.001
FVC (L) 4.0 ± 0.9 3.8 ± 0.8 2.7 ± 0.8* 2.7 ± 1.1* <0.05
FVC (%) 110.8 ± 14.4 111.6 ± 16.9 90.8 ± 24.1* 89.5 ± 19.9* <0.001
FEV1/FVC (%) 83.2 ± 14.8 78.0 ± 4.9 49.0 ± 12.8* 53.5 ± 12.1* <0.05
Packs-year 0.0(0.0-0.0) 30.0(21.3-40.0)† 50.0(29.1-62.5)† 44.0(32,0-60.0)† <0.05
SpO2 (%) 96.6 ± 1.4 96.5 ± 1.5 91.2 ± 5.5* 93.4 ± 3.6* <0.05
BMI (kg/m2) 25.5 ± 3.3 23.8 ± 3.9 25.4 ± 5.5 25.1 ± 4.7 0.48
FFM (kg) 46.3 ± 8.6 44.6 ± 7.4 42.0 ± 7.4 38.3 ± 7.1† 0.01
FFMI (kg/m2) 17.3 ± 1.8 16.5 ± 1.9 16.1 ± 2.4 15.3 ± 1.9† 0.005
Values are expressed as mean (SD) or median (range).
Differences between groups were tested using one way analysis of variance (ANOVA) followed by the Tukey test to account for multiple 
comparisons. Differences between proportions were tested using Chi-square.
* compared to never-smoker controls and current smokers controls. † compared to never-smoker controls. †† compared to never-smoker 
controls, current smoker controls and ex-smokers COPD. § difference in proportion of gender within COPD groups.
M/F: male/female, FVC: forced vital capacity, FEV1: forced expiratory volume in the first second, SpO2: percentage arterial oxygen saturation, 
BMI: body mass index, FFM: fat free mass, FFMI: fat free mass index.Tanni et al. Journal of Inflammation 2010, 7:29
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We could not identified studies designed to assess the
influence of active smoking on plasma TNF-α concentra-
tion in COPD patients. Higashimoto et al. showed
increased levels of serum TNF-α, IL-6 and tissue inhibi-
tors of metalloproteinase-1 in asthma and COPD patients
when compared to control subjects. In the subgroups
analysis, in partial agreement with our findings, they
showed increased levels of TNF-α in current smoker with
COPD when compared to ex-smoker COPD patients;
however , they failed to show higher levels of TNF-α in
current smoker control subjects when compared to non-
current smoker control subjects [12]. Vernooy et al. com-
pared local and systemic inflammation in a small sample
of COPD patients (ex-smokers = 6; current smokers = 12)
and did not show influence of smoking on plasma con-
centration of soluble TNF receptors (sTNF-R55 and
sTNF-R75) [16]. Although the TNF receptors are consid-
ered to be markers of a proinflammatory state inducible
by cytokines such as TNF-α, they present different bio-
logical functions [24,25]. In summary, our results bring
new evidence related to the influence of active smoking
on TNF-α plasma concentration in control subjects and
COPD patients.
There is consensus about the presence of small airway
and lung parenchyma inflammation in smokers and
COPD patients [3,4,16,26-28]. Local inflammation is
characterized by increased numbers of inflammatory
cells, such as neutrophils, lymphocytes, and macrophages
and higher TNF-α and IL-8 concentrations than healthy
controls [1,3,4,26,27,29-32]. However, it is unclear
whether established inflammation in smokers returns to
normal after smoking cessation [2,33]. In a recent study,
Gamble et al. 2007 compared bronchial biopsies of COPD
current smokers and COPD ex-smokers and did not find
any differences in cell counts or inflammatory markers
(CD8+, CD4+, CD 68+, or TNF-α) between groups [2]. In
another study, neutrophil and lymphocyte numbers, and
IL-8 concentration in the sputum of COPD patients
increased one year after smoking cessation [33].
Smoking cessation is the only management measure
associated with reduced FEV1 decline in COPD patients
[5,17]; however, to date, no reduction in airway inflam-
mation has been demonstrated when ex-smokers are
compared to current smokers [2,33]. We speculate that
the association of smoking with systemic TNF-α concen-
trations observed in this study may partially explain some
of the benefit associated with smoking cessation
[17,34,35].
Our results showed higher serum CRP and IL-6 levels
in COPD patients than in never-smoker and current
smoker controls. Several previous studies have also
shown higher serum CRP levels in COPD patients than in
no-smoking controls and current smokers [8,11,36].
Higher CRP concentration has been associated with air-
way obstruction severity, increased resting energy expen-
diture, and impaired exercise capacity and quality of life
in COPD patients [15,37]. Although there is little data
regarding IL-6 concentration in COPD patients [8,9], in
agreement with our findings elevated serum IL-6 levels
h a v e  b e e n  s h o w n  i n  C O P D  p a t i e n t s  c o m p a r e d  t o  n o -
smoker controls [15,36,38].
No influence of airway obstruction severity and use of
LTOT on systemic inflammation in COPD patients was
observed in our study. This result is in contrast with find-
ings of a recent report showing higher serum TNF-α lev-
els in COPD patients with FEV1 < 30% in comparison
with mild-moderate COPD patients; however, the com-
parison between groups was not adjusted for smoking
status of the patients [40]. In agreement with previous
findings no difference in inflammatory markers was also
shown when COPD patients with and without FFM
depletion were compared [39,40]. In addition, we did not
show influence of inhaled corticosteroids on systemic
inflammation in COPD patients. However, when we clas-
sified the COPD patients according GOLD classes, use of
LTOT or inhaled corticosteroids we had few patients to
compare between groups and poor power to detect
potential differences.
Table 2: Systemic inflammation in never-smoker controls, current smokers controls, COPD ex-smokers and COPD current 
smokers
Never-smoker controls
N = 34
Current smoker controls
N = 24
COPD ex-smokers
N = 53
COPD current smokers
N = 24
TNF-α(pg/mL) 3.7 (3.4-4.0) 4.8 (4.2-6.1) * 4.3 (3.9-4.9) ‡ 4.8(4.2-5.8) *
IL-6 (pg/mL) 0.35 (0.21-0,44) 0.42 (0.29-0.81) 0.88 (0.52-1.41) ‡† 0.83(0.46-1.33) ‡
IL-8 (pg/mL) 5.47 (4.45-7.85) 5.68 (4.32-8.35) 5.53 (3.87-11.82) 5.77(3.87-10.53)
CRP (pg/L) 1.10 (0.62-2.00) 1.07 (0.56-2.54) 4.65 (1.62-7.92) ‡† 6.85(2.97-9.39)‡†
TNF-α:Tumor necrosis factor alpha, IL-6: interleukin 6, IL-8: interleukin 8, CRP: C-reative protein. Kruskal-Wallis test followed by Dunn's Method 
to account for multiple comparisons.
* p < 0.05 when compared to never-smoker controls and COPD ex-smokers. ‡ p < 0.05 when compared to never-smoker controls. † p < 0.05 
when compared to current smoker controls.Tanni et al. Journal of Inflammation 2010, 7:29
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There were other limitations to this study. Firstly, the
analyses were performed using cross sectional data and
therefore valid inferences regarding causal pathways can-
not be drawn. Secondly, we did not analyze local inflam-
mation and some data suggest that local and systemic
inflammation can be regulated differently [16].
Conclusions
In conclusion, smoking is associated with higher levels of
TNF-alpha mediated systemic inflammation in patients
with or without COPD. In patients with COPD, who
already have elevated levels of TNF-alpha, active smoking
may associated with even higher degree of the systemic
inflammation. Longitudinal studies evaluating the effects
Table 3: Regression models with robust standard errors for TNF-α, IL-6, IL-8 and CRP
Model Unadjusted (95% confidence interval) Adjusted (95% coefidence interval)
TNF-α(pg/mL)
Current smoking status (yes) 1.032 (0.592,1.471) 1.224 (0.724,1.724)
Presence of disease (COPD) (yes) 0.323 (-0.049,0.696) 0.110 (-0.457,0.677)
Age (years) -- 0.018 (-0.009,0.415)
Gender (Male) -- 0.0005 (-0.6048,0.6049)
SpO2 (%) -- -0.018 (-0.056,0.019)
FFM (kg) -- 0.028 (-0.008,0.066)
IL-6 (pg/mL)
Current smoking status (yes) 0.110 (-0.183,0.404) 0.185 (-0.177,0.547)
Presence of disease (COPD) (yes) 0.621 (0.382,0.861) 0.270 (-0.028,0.569)
Age (years) -- 0.019 (-0.001,0.038)
Gender (Male) -- -0.022 (-0.329,0.284)
SpO2 (%) -- -0.022 (-0.065,0.021)
FFM (kg) -- -0.004 (-0.029,0.020)
CRP (mg/L)
Current smoking status (yes) 0.893 (-2.379,4.165) 2.447 (-1.025,5.918)
Presence of disease (COPD) (yes) 6.834 (3.673,9.994) 4.939 (0.958,8.920)
Age (years) -- 0.175 (0.006,0.344)
Gender (Male) -- -0.494 (-3.361,2.372)
SpO2 (%) -- 0.028 (-0.433,0.488)
FFM (kg) -- 0.141 (-0.018,0.302)
IL-8 (pg/mL)
Current smoking status (yes) -0.829 (-13.738,12.080) -3.836 (-19.490,11.818)
Presence of disease (COPD) (yes) 11.479 (-0.889,23.847) 24.361 (-0.287,49.009)
Age (years) -- -0.516 (-1.272,0.240)
Gender (Male) -- -4.121 (-21.129,12.888)
SpO2 (%) -- 1.205 (-0.842,3.254)
FFM (kg) -- 0.831 (-2.633,0.799)
TNF-α: tumor necrosis factor-alpha; IL-6: interleukin 6; IL-8: interleukin 8; CRP: C-reactive protein; SpO2: peripheral saturation; FFM: fat free 
mass.
Multiple regression with robust standard erros for the analysis of association of current smoking status and presence (COPD) on systemic 
inflammation (TNF-α, IL-6, CRP and IL-8). The first column shows models without adjustment and the second column shows models with 
adjustment.Tanni et al. Journal of Inflammation 2010, 7:29
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of smoking cessation on bronchial and systemic inflam-
mation are needed to allow better understanding of these
relationships and their consequences.
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